Evidence map›Paper›PMID 40815102›Full record

ArticleJournal of the American Chemical Society2025

A Chemo-Enzymatic Platform for Furanolide Synthesis and Functional Exploration.

Xiaoqi Ji, Manuel Einsiedler, Paul M D'Agostino, Jennifer Herrmann, Rolf Müller, Tobias A M Gulder

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoqi JiChair of Technical Biochemistry, Technische Universität Dresden, Bergstraße 66, 01069 Dresden , Germany.
Manuel EinsiedlerChair of Technical Biochemistry, Technische Universität Dresden, Bergstraße 66, 01069 Dresden , Germany.ORCID 0000-0001-5275-3758
Paul M D'AgostinoChair of Technical Biochemistry, Technische Universität Dresden, Bergstraße 66, 01069 Dresden , Germany.ORCID 0000-0002-8323-5416
Jennifer HerrmannDepartment of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), PharmaScienceHub (PSH), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy at Saarland University, Campus E8.1, 66123 Saarbrücken, Germany.ORCID 0000-0003-3398-9938
Rolf MüllerDepartment of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), PharmaScienceHub (PSH), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy at Saarland University, Campus E8.1, 66123 Saarbrücken, Germany.
Tobias A M GulderChair of Technical Biochemistry, Technische Universität Dresden, Bergstraße 66, 01069 Dresden , Germany.ORCID 0000-0001-6013-3161

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Furanolides represent an emerging class of natural products known for their structural diversity and potent bioactivities, including antibiotic, cytotoxic, or algicidal effects. The systematic exploration of their biological activity profiles for the discovery of new hits for drug development thus constitutes a promising endeavor. However, their low natural abundance and the resulting difficulty in obtaining sufficient quantities have limited further in-depth investigations into their biological activity and structure-activity relationships (SARs). Building on our recent discovery of biosynthetic enzymes catalyzing furanolide core-structure assembly, we herein developed a cost-effective, one-pot enzymatic toolbox that enables the fast generation of hundreds of furanolide structural analogs. We systematically evaluated antimicrobial activities and cytotoxicity against the A549 lung cancer cell line for a representative selection of library congeners and explored their SARs. Several derivatives demonstrated significant cytotoxicity, particularly against lung cancer stem cells, offering promising insights into the development of furanolides as potential anticancer agents. Additionally, some analogs displayed promising antibacterial activity against important Gram-positive pathogens such as

Indexed as

Anti-Bacterial AgentsAntineoplastic AgentsA549 CellsCell Line, TumorDrug Screening Assays, AntitumorHumansMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipAnti-Bacterial AgentsAntineoplastic Agents

Identifiers

PMID40815102
PMCPMC12395478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.